Prognostically relevant gene signatures of high-grade serous ovarian carcinoma

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 517-525

  Verhaak, Roel G W ^a   Tamayo, Pablo ^b   Yang, Ji Yeon ^a   Hubbard, Diana ^b,c   Zhang, Hailei ^c   Creighton, Chad J ^d   Fereday, Sian ^e   Lawrence, Michael ^b   Carter, Scott L ^b,c   Mermel, Craig H ^b,c   Kostic, Aleksandar D ^b,c   Etemadmoghadam, Dariush ^e   Saksena, Gordon ^b   Cibulskis, Kristian ^b   Duraisamy, Sekhar ^c   Levanon, Keren ^c,f   Sougnez, Carrie ^b   Tsherniak, Aviad ^b   Gomez, Sebastian ^b   Onofrio, Robert ^b   Gabriel, Stacey ^b   Chin, Lynda ^b,c   Zhang, Nianxiang ^a   Spellman, Paul T ^g   Zhang, Yiqun ^d   Akbani, Rehan ^a   Hoadley, Katherine A ^h   Kahn, Ari ⁱ   Köbel, Martin ^j   Huntsman, David ^k   Soslow, Robert A ^l   Defazio, Anna ^m   Birrer, Michael J ⁿ   Gray, Joe W ^g   Weinstein, John N ^a   Bowtell, David D ^e   Drapkin, Ronny ^c   Mesirov, Jill P ^b   Getz, Gad ^b   Levine, Douglas A ^l   Meyerson, Matthew ^b,c   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f SHEBA MEDICAL CENTER   (Israel)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ GENERAL DYNAMICS   (United States)

^j UNIVERSITY OF CALGARY   (Canada)

^k BRITISH COLUMBIA CANCER AGENCY   (Canada)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE MUTATION; HIGH GRADE SEROUS OVARIAN CARCINOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVARY CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; VALIDATION STUDY;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; MUTATION; NEOPLASM GRADING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84873862912     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65833     Document Type: Article

References (51)

1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24): 2519-2529.
2. Kobel M, et al. Differences in tumor type in lowstage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3): 203-211.
3. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6): 415-428.
4. Markman M, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21(13): 2460-2465.
5. Jemal A, Siegel R, Xu JQ, Ward E. Cancer Statis tics, 2010. Ca-a Cancer Journal for Clinicians. 2010; 60(5): 277-300.
6. Coleman MP, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760): 127-138.
7. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8): 573-584.
8. Spentzos D, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004;22(23): 4700-4710.
9. Crijns AP, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6(2):e24.
10. Bonome T, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68(13): 5478-5486.
11. Jazaeri AA, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11(17): 6300-6310.
12. Hartmann LC, et al. Gene expression profiles predict early relapse in ovarian cancer after platinumpaclitaxel chemotherapy. Clin Cancer Res. 2005; 11(6): 2149-2155.
13. Reed E. ERCC1 and clinical resistance to platinumbased therapy. Clin Cancer Res. 2005;11(17): 6100-6102.
14. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004; 10(13): 4420-4426.
15. Helleman J, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 2006;6:201.
16. van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25): 1999-2009.
17. Paik S, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27): 2817-2826.
18. Wang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365(9460): 671-679.
19. Lai A, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2): 142-148.
20. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353): 609-615.
21. Network T. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216): 1061-1068.
22. Ahmed AA, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1): 49-56.
23. Tothill RW, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16): 5198-5208.
24. Marquez RT, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11(17): 6116-6126.
25. Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1): 98-110.
26. Park JT, et al. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006;66(12): 6312-6318.
27. Winslow MM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011; 473(7345): 101-104.
28. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12): 1739-1740.
29. Denkert C, et al. A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol. 2009;218(2): 273-280.
30. Dressman HK, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007;25(5): 517-525.
31. Yoshihara K, et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One. 2010;5(3):e9615.
32. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645): 643-646.
33. Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8): 1160-1167.
34. Konstantinopoulos PA, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22): 3555-3561.
35. Huang RS, et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011; 17(16): 5490-5500.
36. Etemadmoghadam D, et al. Integrated genomewide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009;15(4): 1417-1427.
37. Bolton KL, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012; 307(4): 382-390.
38. Yang D, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14): 1557-1565.
39. Katsumata N, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, openlabel, randomised controlled trial. Lancet. 2009; 374(9698): 1331-1338.
40. Fong PC, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2): 123-134.
41. Ledermann J, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15): 1382-1392.
42. Wang XV, Verhaak RG, Purdom E, Spellman PT, Speed TP. Unifying gene expression measures from multiple platforms using factor analysis. PLoS One. 2011;6(3):e17691.
43. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98(9): 5116-5121.
44. Liu H, et al. AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics. 2007;23(18): 2385-2390.
45. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2): 249-264.
46. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. The WEKA data mining software: an update. SIGKDD Explor Newsl. 2009;11: 10-18.
47. Hall MA. Correlation-Based Feature Selection For Machine Learning [PhD thesis}. Hamilton, New Zealand: Waikato University; 1999.
48. Creighton CJ, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008;26(25): 4078-4085.
49. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43): 15545-15550.
50. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
51. Levanon K, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010;29(8): 1103-1113.